Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lisbon
Clinical trial register · Portugal

Clinical Trials in Lisbon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 683 Porto 541 Coimbra 258 Braga 180 Vila Nova de Gaia 108
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca33 Janssen Research & Development, LLC32 Merck Sharp & Dohme LLC28 Hoffmann-La Roche27 Novartis Pharmaceuticals27
Site location
Lisbon683 Porto541 Coimbra258 Braga180 Vila Nova de Gaia108
All 96 locations
Target enrolment
to

Trials with a site in Lisbon

683 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Not yet open
Target Physiotherapy Versus Exercise Support Intervention for Bladder-bowel Dysfunction in Adolescents With Obesity
NCT07724158Bladder-Bowel Dysfunction, Obesity & Overweight
University of Lisbon
Not applicable
237
Lisbon
2027-01-04
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Vila Nova de Gaia, Lisbon, Loures, Porto
2026-12-16
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Lisbon, Vila Nova de Gaia, Braga, Porto
2026-11-30
Not yet open
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819Advanced Solid Tumor
DrugsPM54·Doxorubicin·Irinotecan
PharmaMar
Phase 1/2
231
Lisbon, Porto
2026-11-12
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Aveiro, Coimbra, Lisbon
2026-11-09
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Coimbra, Lisbon, Porto
2026-09-11
Not yet open
An Open-label, Single-arm Interventional Study to Evaluate the Safety and Efficacy of a Probiotic-containing Cream in Children With Dry Skin
NCT07713303Dry Skin
BioGaia AB
Not applicable
40
Lisbon
2026-09-01
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Lisbon, Porto
2026-09
Not yet open
Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study
NCT07772544Psoriatic Arthritis (PsA)
Sociedade Portuguesa de Reumatologia
Not applicable
72
Aveiro, Lisbon, Porto
2026-09
Not yet open
Family-centred Pulmonary Rehabilitation to Empower Carers
NCT07791147Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Asthma, Lung Neoplasms
Aveiro University
Not applicable
120
Aveiro, Santa Maria da Feira, Figueira da Foz Municipality, Lisbon, Matosinhos Municipality, Vila Nova de Gaia
2026-09
Not yet open
Feasibility and Preliminary Outcomes of the Brave Elephant Program: A Single-Arm Pretest-Posttest Study
NCT07567820Anxiety
ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida
Not applicable
60
Lisbon
2026-09
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714Systemic Lupus Erythematosus
AstraZeneca
Phase 2
24
Lisbon, Porto
2026-08-31
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Braga, Lisbon, Porto
2026-08-31
Recruiting
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
NCT07784387Urinary Bladder Neoplasms
Janssen-Cilag Farmaceutica Ltda.
Observational
250
Lisbon
2026-08-25
Recruiting
CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
NCT07809659Ovarian Cancer
Instituto Portugues Oncologia de Lisboa Francisco Gentil
Not applicable
2,130
Lisbon
2026-08-06
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504Overweight, Obesity
DrugCagrilintide
Novo Nordisk A/S
Phase 3
285
Caldas da Rainha, Figueira da Foz Municipality, Leiria, Lisbon, Vila Nova de Gaia
2026-08-04
Recruiting
Innovative Ovarian Cancer Biomarker Assays
NCT07693894Ovarian Cancer
National and Kapodistrian University of Athens
Observational
2,080
Lisbon
2026-08-03
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Almada, Coimbra, Lisbon, Ponte de Lima, Porto
2026-07-27
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
DrugNerandomilast
Boehringer Ingelheim
Phase 3
35
Lisbon
2026-07-21
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Lisbon, Porto
2026-07-10
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
Guimarães, Lisbon
2026-07-08
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Coimbra, Lisbon, Porto, Torres Vedras
2026-07-01
Not yet open
Evaluation of the Effect of Combined Use of Cosmetic Products for Dry and Itchy Skin.
NCT07695805Dry Skin
Lacer S.A.
Not applicable
60
Lisbon
2026-07
Not yet open
Exogenous Progesterone as Ovulation Trigger
NCT07466199Ovulation, Ovarian Function, Assisted Reproductive Treatments, Oocyte Maturation
DrugsVaginal micronized progesterone·Cyclogest
Instituto Valenciano de Infertilidade de Lisboa
Phase 4
10
Lisbon
2026-07
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Braga, Lisbon, Porto
2026-06-30
Recruiting
Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum
NCT07342608Bradycardia, Left Bundle Branch Area Pacing, Left Bundle Branch Pacing
MicroPort CRM
Not applicable
450
Coimbra, Lisbon
2026-06-23
Recruiting
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
NCT07507760Acute Myeloid Leukemia With Gene Mutations
DrugsDecitabine/Cedazuridine·Hydroxyurea·Ivosidenib·Cytarabine
PETHEMA Foundation
Phase 2
50
Aveiro, Funchal, Lisbon, Porto
2026-06-12
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Coimbra, Lisbon, Porto
2026-06-01
Not yet open
CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
NCT07630246Lung Adenocarcinoma
Universidade Nova de Lisboa
Observational
140
Lisbon
2026-06-01
Recruiting
BIO|STREAM.CSP Study
NCT07393009Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices
Biotronik SE & Co. KG
Observational
1,000
Coimbra, Lisbon
2026-05-25
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Braga, Lisbon
2026-05-23
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Guimarães, Loures, Almada, Lisbon, Porto
2026-05-22
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Riachos, Torres Novas, Almada, Caldas da Rainha, Figueira da Foz Municipality, Lisbon, Senhora Da Hora, Matosinhos, Vila do Conde, Vila Nova de Gaia
2026-05-21
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
Amadora-Lisbon, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
2026-05-21
Not yet open
Impact of a Wheat-based Fermented Beverage on Microbiota and Metabolic Health in Healthy Individuals
NCT07560527Health Adult Subjects
Universidade Nova de Lisboa
Not applicable
20
Lisbon
2026-05-20
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Alcabideche, Almada, Braga, Lisbon, Porto, Senhora Da Hora, Matosinhos, Vila Nova de Gaia
2026-05-20
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 3
350
Lisbon, Porto, Coimbra
2026-05-14
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
DrugsAdagrasib·Fluorouracil·Leucovorin·Cetuximab
Mirati Therapeutics Inc.
Phase 2
170
Lisbon
2026-05-06
Recruiting
ClusterVAP: Multicentre Proteomic Endotyping of Ventilator-associated Pneumonia
NCT07245888Ventilator Acquired Pneumonia, Mechanical Ventilation Complication
Region Skane
Observational
400
Lisbon
2026-05-01
Not yet open
Home Monitoring in eAMD Treatment
NCT07340372Exudative Age-Related Macular Degeneration
DrugAflibercept
Association for Innovation and Biomedical Research on Light and Image
Observational
80
Coimbra, Leiria, Lisbon, Loures, Porto
2026-05
Recruiting
Multicenter Cardiac Decision Impact Study in People With Breast Cancer
NCT07703033Breast Cancer, Cardiovascular (CV) Risk, Coronary Artery Calcifications
UMC Utrecht
Not applicable
1,000
Lisbon
2026-04-20
Recruiting
Transcultural Digital Solutions in Phase III Cardiac Rehabilitation
NCT07252856Heart Failure, Myocardial Infarction
Fondazione Don Carlo Gnocchi ETS
Not applicable
306
Lisbon
2026-04-20
Recruiting
PSYCHOPATHY.COMP Program Among Male Prison Inmates With Psychopathy
NCT07481253Antisocial Personality Disorder (ASPD)
University of Coimbra
Not applicable
200
Lisbon
2026-04-06
Recruiting
Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
NCT07316621Crohn Disease (CD)
GLSMED Learning Health S.A.
Observational
10,000
Lisbon
2026-04-01
Not yet open
Study of Functional Decline and Care Pathways in Neurosurgical Patients Over 65 Years of Age
NCT07506941Ageing and Geriatric Health
University Hospital, Toulouse
Observational
209
Lisbon
2026-04-01
Not yet open
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729B-Cell Acute Lymphoblastic Leukaemia
DrugsInotuzumab Ozogamicin·Blinatumomab
Charite University, Berlin, Germany
Phase 3
750
Lisbon
2026-04-01
Not yet open
Combined Exercise Effects in Breast Cancer-related Lymphedema
NCT07365618Breast Cancer-Related Lymphedema
Faculdade de Motricidade Humana
Not applicable
58
Lisbon
2026-04
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Braga, Lisbon, Santa Maria da Feira
2026-03-26
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Lisbon, Porto
2026-03-24
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Almada, Braga, Lisbon, Loures
2026-03-23
Recruiting
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
NCT07711821Heart Failure
Universidade do Porto
Not applicable
160
Amadora, Lisbon, Porto
2026-03-23
Recruiting
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
NCT07235592Primary Open Angle Glaucoma
Santen SAS
Observational
112
Lisbon
2026-03-19
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Lisbon, Porto
2026-03-17
Not yet open
Wireless Assessment of Respiratory and Circulatory Distress - Europe
NCT07451249Patient Deterioration, Patient Monitoring, Clinical Deterioration
Eske Kvanner Aasvang
Not applicable
1,240
Lisbon
2026-03-16
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Braga, Lisbon
2026-03-12
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Braga, Coimbra, Lisbon, Santa Maria da Feira
2026-03-10
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Almada, Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2026-03-05
Recruiting
CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer
NCT06734156Colorectal Cancer (CRC), Microbiome, Early Onset Colorectal Cancer
Gulbenkian Institute for Molecular Medicine
Observational
400
Lisbon
2026-03-02
Recruiting
To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
NCT07493421Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer
Unidade Local de Saúde São João, Oporto
Not applicable
20
Lisbon, Porto
2026-03-01
Not yet open
Understanding and Responding to Grief-Related Needs: A Differentiated Community Approach
NCT07433101Prolonged Grief Disorder (PGD)
ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida
Not applicable
246
Lisbon
2026-03-01
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Almada, Amadora, Braga, Coimbra, Lisbon, Loures, Porto, Setúbal
2026-02-16
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Lisbon, Porto
2026-02-03
Recruiting
UL Smile: A Mobile Health Application to Promote Oral Health in Portuguese Adolescents
NCT07276191Oral Health Care, Oral Health Behavior Change, Oral Health Self-efficacy
University of Lisbon
Not applicable
150
Lisbon
2026-02-02
Recruiting
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT07402915Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal
DrugsTorvutatug samrotecan·Itraconazole
AstraZeneca
Phase 1
32
Lisbon
2026-01-26
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Eikon Therapeutics
Phase 1/2
160
Lisbon, Loures
2026-01-20
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Lisbon, Porto
2026-01-16
Recruiting
Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping
NCT07320560Atrial Fibrillation (AF)
German Heart Institute
Not applicable
45
Lisbon
2026-01-15
Recruiting
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
NCT07343674Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)
Portuguese Association of Interventional Cardiology
Observational
500
Coimbra, Lisbon, Funchal, Porto, Vila Nova de Gaia, Evora
2026-01-14
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459Idiopathic Pulmonary Fibrosis
Contineum Therapeutics
Phase 2
324
Lisbon
2026-01-08
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Almada, Lisbon
2026-01-07
Active, closed
Effects of Exercise Snacking on Physical Fitness, Cognition, and Pain in Institutionalized Older Adults
NCT07335068Chronic Pain, Cognition Disorders in Old Age, Physical Fitness in Older Adults
Ivan Patrício
Not applicable
75
Lisbon
2026-01-05
Not yet open
Effectiveness of the DMHI and OPS Platform in Improving Participant QOL: a Randomised Controlled Trial.
NCT07276451Anxiety, Depression and Quality of Life, Quality of Life
Universidade Nova de Lisboa
Not applicable
82
Lisbon
2026-01-01
Recruiting
Promoting Socioemotional Development in Early Childhood: Implementation and Evaluation of the VIPP-SD Parenting Intervention in Portugal
NCT07153198Parent-Child Relations
ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida
Not applicable
120
Lisbon
2026-01-01
Recruiting
Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt
NCT07359547GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Universitaire Ziekenhuizen KU Leuven
Not applicable
166
Lisbon
2026-01-01
Not yet open
Internet Delivered Therapy for Social Anxiety in Adults
NCT06767878Control Group, Intervention
Grupo Lusófona
Not applicable
62
Lisbon
2026-01
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562Multiple Myeloma
DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
1,000
Coimbra, Lisbon
2025-12-23
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
NCT07266428Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2
170
Lisbon
2025-12-17
Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
NCT07293754Advanced Malignant Solid Tumor
Repertoire Immune Medicines
Phase 1/2
150
Lisbon
2025-12-12
Recruiting
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
300
Lisbon
2025-12-11
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Coimbra, Lisbon, Porto
2025-12-09
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Lisbon, Portimão, Porto, Vila Nova de Gaia
2025-12-03
Recruiting
Tuning in to Kids® for Parents of Preschool-aged Children in Portugal
NCT07350083Parental Emotion Socialization, Parents' Beliefs About and Reactions to Children's Emotions, Parental Emotion Regulation
Lusofona University
Not applicable
152
Lisbon
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Coimbra, Guimarães, Lisbon, Senhora da Hora, Torres Vedras
2025-12-02
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Lisbon, Porto, Vila Nova de Gaia
2025-11-28
Recruiting
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT07281833Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugCapivasertib
Women's Cancer Study Group GmbH
Phase 3
250
Lisbon
2025-11-27
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
285
Lisbon, Porto
2025-11-27
Recruiting
Regional Versus General Anesthesia for Hip Fracture and Postoperative Oxygenation
NCT07309575Hip-fracture, General Anaesthesia, Regional Anaesthesia
University of Lisbon
Observational
102
Lisbon
2025-11-27
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Aveiro, Coimbra, Lisbon, Setúbal
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Braga, Coimbra, Funchal, Guimarães, Lisbon, Matosinhos Municipality, Torres Vedras
2025-11-24
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Carnaxide, Coimbra, Lisbon, Porto
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Torres Novas, Lisbon, Porto, Vila Nova de Gaia
2025-11-19
By invitation
Determination of Clinical Phenotypes of Intrauterine Growth Restriction in Term Infants Based on Body Composition
NCT07483424Intrauterine Growth Restriction (IUGR)
Centro Hospitalar de Lisboa Central
Observational
290
Lisbon
2025-11-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Coimbra, Lisbon, Porto
2025-11-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Braga, Lisbon, Porto
2025-11-11
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Braga, Coimbra, Lisbon, Porto
2025-11-07
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Coimbra, Lisbon, Porto
2025-11-05
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Coimbra, Lisbon, Porto
2025-11-03
Recruiting
Changes in Oral Health-related Quality of Life (OHRQoL) During Full Arch Implant Treatment
NCT07568249Edentulous Mouth, Quality of Life, Tooth Loss, Oral Health Quality of Life (OHQoL) Was Assessed
Implantology Institute
Observational
100
Lisbon
2025-11-01
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Coimbra, Lisbon, Porto
2025-10-27
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Lisbon, Porto
2025-10-24
Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
DrugSaccharomyces boulardii
Biocodex
Phase 3
406
Braga, Lisbon
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
100
Lisbon, Vila Nova de Gaia
2025-10-21
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Lisbon
2025-10-17
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Lisbon
2025-10-15
Not yet open
Testing a Smart Medication Dispenser (Mobili®) to Help People With Chronic Conditions Take Their Medicine
NCT07175545Dose Administration Aids, Medication Adherence, Polypharmacy, Technology in Health
Lusofona University
Not applicable
96
Lisbon
2025-10-15
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
Lisbon, Porto
2025-10-13
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
Guimarães, Lisbon
2025-10-06
Recruiting
Evaluation of the Safety and Performance of the Neocement® Inject P: A Prospective Observational Study in Dental Area
NCT07179510Bone Augmentation
Bioceramed
Observational
66
Lisbon
2025-10-06
Recruiting
Evaluation of the Safety and Performance of the Neobone®: A Prospective Observational Study in Dental Area
NCT07179497Bone Augmentation
Bioceramed
Observational
66
Lisbon
2025-10-06
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Braga, Guimarães, Lisbon, Loures, Porto
2025-10-03
Not yet open
Better4All Personalized Intervention
NCT06997510Obesity Prevention
Harokopio University
Not applicable
1,022
Lisbon
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Braga, Guimarães, Lisbon, Loures, Porto, Viana do Castelo
2025-10-01
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
NCT07285590Mantle Cell Lymphoma (MCL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
50
Lisbon
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
710
Lisbon
2025-09-30
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
Lisbon
2025-09-23
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Almada, Baixa Da Banheira, Carnaxide, Coimbra, Creixomil, Leiria, Lisbon, Loures
2025-09-22
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Lisbon, Coimbra, Porto
2025-09-11
Recruiting
Evaluation of the Safety and Performance of the Hydrustent® Biodegradable Hydrogel Ureteral Stent
NCT06719089Urinary Lithiasis
Hydrumedical
Not applicable
134
Aveiro, Guimarães, Lisbon, Viana do Castelo
2025-09-09
Active, closed
Professional Training Programs Targeting Attendance in Fitness Centers
NCT07156240Exercise Frequency
Grupo Lusófona
Not applicable
117
Lisbon
2025-09-03
Recruiting
More Health Less Diabetes
NCT07079722Pre-diabetes
Faculdade de Motricidade Humana
Not applicable
90
Lisbon
2025-09-01
Recruiting
Cardiac Remodelling Following Endovascular Repair of the Aorta
NCT07415447Cardiac Failure, Aortic Disease
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Observational
40
Lisbon
2025-09-01
Not yet open
Effects of Heart Rate Variability-guided Training vs Standard Aerobic Prescription on Cardiovagal Modulation and Cardiorespiratory Fitness in Coronary Artery Disease
NCT06919237Coronary Arterial Disease (CAD)
Faculdade de Motricidade Humana
Not applicable
48
Lisbon
2025-09-01
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Lisbon, Loures
2025-08-26
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Lisbon, Matosinhos Municipality
2025-08-18
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898Neoplasms, Lung
DrugsRis-Rez·Risvutatug rezetecan·Topotecan
GlaxoSmithKline
Phase 3
420
Almada, Guimarães, Lisbon
2025-08-11
Recruiting
Evaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optic
NCT05955846Intraocular Lens, Cataract, Presbyopia
Z Optics, Inc.
Not applicable
60
Coimbra, Lisbon
2025-08-07
Recruiting
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
NCT06709339Polypoidal Choroidal Vasculopathy
DrugsVabysmo·Faricimab
Association for Innovation and Biomedical Research on Light and Image
Phase 4
120
Coimbra, Leiria, Lisbon, Loures, Porto
2025-08-06
Recruiting
HOPE Against Cancer Recurrence in HCC
NCT06717919Liver Transplantation, HCC, Oncological Outcomes
Philipp Dutkowski
Phase 4
220
Lisbon
2025-08-01
Active, closed
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365Type 1 Interferonopathies
Boehringer Ingelheim
Phase 1
16
Lisbon, Porto
2025-07-29
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Braga, Carnaxide, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Ponte de Lima, Riachos, Torres Novas
2025-07-25
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
Coimbra, Lisbon, Porto
2025-07-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Lisbon, Braga, Porto
2025-07-23
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Almada, Amadora, Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon
2025-07-22
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Alcabideche, Lisbon, Porto
2025-07-17
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Lisbon
2025-07-14
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Coimbra, Guimarães, Lisbon, Senhora da Hora, Torres Vedras
2025-07-10
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Carnaxide, Creixomil, Leiria, Lisbon, Vila Real, Viseu
2025-07-02
Recruiting
Psilocybin Therapy for Psychological Distress in Palliative Patients
NCT06782724COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
University Medical Center Groningen
Phase 2
108
Lisbon
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Lisbon, Porto
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
DrugNizubaglustat
Azafaros B.V.
Phase 3
147
Porto, Lisbon
2025-06-30
Active, closed
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1
DrugNizubaglustat
Azafaros B.V.
Phase 3
75
Porto, Lisbon
2025-06-30
Active, closed
Preliminary Efficacy of AdoptMindful2Care: A Mindful Parenting Post-adoption Intervention for Adoptive Parents
NCT07043660Parenting Stress
University of Coimbra
Not applicable
78
Aveiro, Coimbra, Lisbon, Porto
2025-06-30
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
DrugsCDK4/6i·Trastuzumab deruxtecan
MedSIR
Phase 2
200
Lordelo, Alcabideche, Amadora, Aveiro, Braga, Lisbon, Loures, Porto
2025-06-30
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Lisbon, Porto
2025-06-27
Recruiting
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy
NCT07483827C3 Glomerulopathy (C3G), Healthy Adult Participants
eleva GmbH
Phase 1
39
Lisbon
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2025-06-25
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Braga, Coimbra, Lisbon
2025-06-23
Recruiting
AI-Driven Model Impact on Patient Engagement in Medically Assisted Reproduction
NCT07087171Infertility (IVF Patients), Artificial Intelligence (AI)
Instituto Valenciano de Infertilidade de Lisboa
Observational
774
Lisbon
2025-06-11
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Braga, Faro, Lisbon, Almada, Funchal
2025-06-09
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon, Porto
2025-06-09
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Lisbon, Porto
2025-06-04
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Lisbon, Porto
2025-06-04
Recruiting
Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke
NCT07232498Arterial Ischemic Stroke
Unidade Local de Saúde de Coimbra, EPE
Not applicable
1,300
Coimbra, Lisbon, Porto
2025-06-04
Active, closed
VA|PREVENTION: Randomized Controlled Trial of a Person-Centred Digital Intervention to Prevent Diabetes in High-Risk Adults
NCT07021144Pre-diabetes, Pre-diabetic State
Egas Moniz - Cooperativa de Ensino Superior, CRL
Not applicable
180
Almada, Seixal, Alcabideche, Amadora, Barreiro, Caparica, Costa da Caparica, Lisbon
2025-06-03
Recruiting
AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing
NCT07614542Menopause, Gut Microbiome, Hormonal Changes, Chronic Low-Grade Inflammation
Gulbenkian Institute for Molecular Medicine
Observational
300
Lisbon
2025-06-02
Recruiting
Better4All Personalized Intervention Pilot Study
NCT07120802Obesity Prevention
Harokopio University
Not applicable
490
Lisbon
2025-06-01
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Lisbon, Porto
2025-05-29
Recruiting
Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression
NCT06727253Crohn Disease (CD)
GLSMED Learning Health S.A.
Not applicable
30
Lisbon
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Almada, Braga, Guimarães, Lisbon, Porto
2025-05-22
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Keytruda·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Lisbon
2025-05-22
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Lisbon, Porto
2025-05-19
Recruiting
Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme
NCT06696534Screening for Colon Cancer, Survey and Questionnaire
ADVANCED MARKER DISCOVERY S.L.
Not applicable
1,000
Lisbon
2025-05-19
Recruiting
Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry
NCT06818435Aortic Valve Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Portuguese Association of Interventional Cardiology
Observational
150
Carnaxide, Coimbra, Evora, Lisbon, Porto
2025-05-13
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Lisbon, Porto
2025-05-12
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin
Mirati Therapeutics Inc.
Phase 3
630
Lisbon, Coimbra, Porto
2025-04-24
Active, closed
PURI-PRO - Symptoms Impact and eHealth Intervention for Menopausal Women With Urinary Incontinence
NCT06527638Urinary Incontinence
ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida
Not applicable
80
Lisbon
2025-04-22
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Guimarães, Leiria, Lisbon, Porto
2025-04-15
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Alcabideche, Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
770
Lisbon, Porto
2025-04-09
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
Braga, Coimbra, Lisbon, Porto
2025-04-08
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Lisbon
2025-04-01
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
Lisbon
2025-03-31
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Coimbra, Lisbon, Porto
2025-03-27
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Almada, Lisbon, Loures, Porto
2025-03-21
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
157
Coimbra, Lisbon
2025-03-20
Recruiting
Revised Targets for Knee Radiofrequency Ablation
NCT06934421Osteoarthritis Knee Pain
Centro Hospitalar Universitario do Algarve
Observational
60
Faro, Lisbon
2025-03-20
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-03-17
Recruiting
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149Ischemic Stroke
DrugsAlteplase·Tenecteplase
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Amadora, Coimbra, Funchal, Lisbon, Matosinhos Municipality, Porto
2025-03-14
Active, closed
Anthesis: A Transdiagnostic Cognitive-Behavioral Therapy (CBT)-Based Approach to Sexual Distress: Testing a Pilot Online Intervention
NCT06823973Sexual Distress, Sexual Dysfunctions
Grupo Lusófona
Not applicable
30
Lisbon
2025-03-07
Recruiting
Inari VISION Registry
NCT06600542Pulmonary Embolism
Inari Medical
Observational
1,000
Lisbon
2025-03-07
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Coimbra, Ponte de Lima, Vila Nova de Gaia, Almada, Lisbon
2025-03-03
Recruiting
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe
NCT06856902Cardiovascular Diseases, Endocrinology, Inmunology, Neurology
Technical University of Madrid
Not applicable
3,100
Lisbon, Porto
2025-03-01
By invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
Indiana University
Observational
4,000
Lisbon, Porto
2025-03-01
Not yet open
Urban and Insular Study on Treatment Experiences and Stigma in People Living with HIV
NCT06812910HIV, Stigma, Depression/Anxiety
Fábio Cota Medeiros
Observational
300
Lisbon
2025-03-01
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Braga, Lisbon, Porto, Coimbra, Faro
2025-02-27
Recruiting
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837Acute Myeloid Leukemia, Relapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3
339
Lisbon
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Braga, Guimarães, Lisbon, Porto
2025-02-27
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Lisbon, Ponte de Lima, Vila Nova de Gaia
2025-02-25
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
DrugAtogepant
AbbVie
Phase 3
420
Lisbon, Almada, Coimbra, Porto
2025-02-13
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Coimbra, Lisbon, Porto
2025-02-12
Recruiting
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
University of L'Aquila
Observational
200
Lisbon
2025-02-12
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
Senhora Da Hora, Matosinhos, Lisbon, Porto, Vila Nova de Gaia
2025-02-10
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Guimarães, Lisbon, Loures, Senhora da Hora, Almada, Aveiro, Braga, Porto
2025-02-10
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
875
Coimbra, Lisbon, Porto
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Coimbra, Lisbon, Porto
2025-02-05
Not yet open
cGMP: Metabolism and Appetite Modulation
NCT06794515Healthy
Universidade Nova de Lisboa
Not applicable
15
Lisbon
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Lisbon
2025-02-03
Recruiting
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT06888388Breast Cancer Surgery
Sir Mortimer B. Davis - Jewish General Hospital
Observational
4,700
Lisbon
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Almada, Braga, Coimbra, Lisbon, Porto
2025-01-31
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Braga, Coimbra, Lisbon, Portimão, Porto, Senhora da Hora, Vila Nova de Gaia
2025-01-28
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 3
1,046
Braga, Lisbon, Porto
2025-01-27
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Coimbra, Lisbon, Porto
2025-01-22
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Coimbra, Lisbon, Ponte de Lima, Vila Nova de Gaia
2025-01-15
Recruiting
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
NCT06703632Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma
ADVANCED MARKER DISCOVERY S.L.
Not applicable
4,538
Lisbon
2025-01-14
Recruiting
UP STUDY - Decipher Persistent Critical Illness Through in Deep Clinical Phenotyping.
NCT07510776Critical Illness, Recovery Outcomes, Critical Care, Intensive Care, Critical Care
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Observational
7,000
Lisbon, Vila Nova de Gaia
2025-01-13
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Guimarães, Lisbon, Porto
2025-01-08
By invitation
Domperidone on the Composition of Preterm Breastmilk Using a Human Milk Mid-infrared Spectroscopy Analyzer
NCT06830226Insufficient Breast Milk Syndrome, Premature Birth
Centro Hospitalar de Lisboa Central
Observational
81
Lisbon
2025-01-08
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
Coimbra, Lisbon
2025-01-02
By invitation
Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)
NCT06862479Obesity, Obesity, Morbid, Esophageal Cancer, Esophageal Neoplasms
Unidade Local de Saúde Santa Maria
Observational
180
Lisbon
2025-01-01
Active, closed
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369Non Squamous Non Small Cell Lung Cancer
DrugsEU-sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin
mAbxience Research S.L.
Phase 3
726
Lisbon, Matosinhos Municipality, Porto
2024-12-30
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Braga, Lisbon, Porto
2024-12-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
Lisbon, Porto
2024-12-19
Recruiting
Xeltis Hemodialysis Access (aXess) Conduit: aXess-E Study
NCT06329310End Stage Renal Disease
Xeltis
Not applicable
20
Lisbon
2024-12-16
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2024-12-16
Active, closed
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-12-11
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
60
Coimbra, Lisbon, Porto
2024-12-09
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Lisbon, Vila Nova de Gaia
2024-12-04
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Creixomil, Lisbon, Porto, Viseu
2024-12-03
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Guimarães, Lisbon, Loures, Sintra, Torres Vedras, Coimbra, Porto
2024-11-26
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Lisbon, Porto
2024-11-19
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Lisbon, Porto
2024-11-19
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Lisbon, Porto
2024-11-18
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Lisbon, Vila Nova de Gaia
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Coimbra, Lisbon, Porto
2024-11-11
Recruiting
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
NCT07461909Frozen Embryo Transfer (FET), Infertility, Artificial Cycle, Natural Cycle
Instituto Valenciano de Infertilidade de Lisboa
Observational
400
Lisbon
2024-11-08
Recruiting
Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets
NCT06490965Obsessive-Compulsive Disorder
Fundacao Champalimaud
Not applicable
32
Lisbon
2024-11-07
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Almada, Lisbon
2024-10-24
Active, closed
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
NCT05888922Androgenetic Alopecia, Female Pattern Baldness
DrugMinoxidil
Industrial Farmacéutica Cantabria, S.A.
Phase 3
520
Lisbon, Madeirã
2024-10-17
Active, closed
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
960
Braga, Lisbon, Ponte de Lima
2024-10-15
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
200
Coimbra, Lisbon, Vila Nova de Gaia
2024-10-09
Recruiting
A Women-Focused Cardiovascular Rehabilitation Program on Adherence, Health Related Physical Fitness, and Quality of Life
NCT06472414Cardiovascular Diseases
University of Lisbon
Not applicable
82
Lisbon
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Lisbon, Coimbra, Porto
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Braga, Lisbon, Loures, Porto
2024-10-04
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Loures, Vila Franca de Xira, Porto, Vila Nova de Gaia, Coimbra, Faro, Lisbon, Setúbal
2024-09-27
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Guimarães, Lisbon, Torres Vedras, Matosinhos Municipality
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
96
Coimbra, Lisbon, Porto
2024-09-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Coimbra, Lisbon, Portimão, Porto, Vila Real
2024-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Braga, Faro, Lisbon, Porto
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Braga, Coimbra, Lisbon, Porto
2024-09-23
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Lisbon, Porto
2024-09-18
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-09-17
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
Lisbon, Setúbal
2024-09-17
Active, closed
NEUROPSYCHOLOGICAL REHABILITATION FOR ALCOHOL USE DISORDERS
NCT06933186Alcohol Use Disorder Cognitive Decline
University of Lisbon
Not applicable
48
Lisbon
2024-09-15
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Almada, Lisbon, Porto
2024-09-04
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Guimarães, Lisbon, Braga, Coimbra, Viana do Castelo
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Lisbon, Porto
2024-09-03
Recruiting
Antidandruff Lotion Mediating Microbiome Rebalance
NCT06813521Dandruff
L'Oreal
Not applicable
120
Lisbon
2024-09-01
Active, closed
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,000
Aveiro, Braga, Carnaxide, Castelo Branco, Coimbra, Faro, Funchal, Lisbon
2024-08-30
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Matosinhos Municipality, Coimbra, Lisbon, Porto
2024-08-28
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 2
194
Lisbon, Porto
2024-08-27
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Braga, Coimbra, Lisbon
2024-08-21
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
Lisbon, Porto
2024-08-13
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Lisbon
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Coimbra, Lisbon, Matosinhos Municipality, Porto, Vila Real
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Lisbon, Porto, Vila Nova de Gaia
2024-07-31
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2
660
Santa Maria da Feira, Senhora da Hora, Braga, Coimbra, Lisbon
2024-07-30
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Braga, Leiria, Lisbon, Loures, Ponta Delgada, Porto, Touguinho
2024-07-25
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Almada, Coimbra, Lisbon, Porto
2024-07-19
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Sotorasib·Panitumumab·Mvasi
Amgen
Phase 3
450
Almada, Coimbra, Lisbon, Matosinhos Municipality, Santa Maria da Feira
2024-07-17
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Coimbra, Lisbon, Matosinhos Municipality
2024-07-12
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Aveiro, Braga, Coimbra, Lisbon, Matosinhos Municipality, Porto, Setúbal, Vila Nova de Gaia
2024-07-11
Not yet open
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
NCT06371807Early Breast Cancer, Triple Negative Breast Cancer
DrugsCyclophosphamide·Paclitaxel·Carboplatin·Pembrolizumab
Fundacao Champalimaud
Phase 2
20
Lisbon, Porto
2024-07
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Braga, Lisbon, Porto
2024-06-29
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Guimarães, Lisbon, Porto
2024-06-27
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Coimbra, Lisbon, Porto
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Amadora, Lisbon, Porto
2024-06-24
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Lisbon, Porto
2024-06-19
Active, closed
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122Follicular Lymphoma
DrugsBendamustin·Vincrystine·Mosunetuzumab·Obinutuzumab
The Lymphoma Academic Research Organisation
Phase 3
790
Lisbon
2024-06-07
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297Neutropenia
X4 Pharmaceuticals
Phase 3
176
Aveiro, Coimbra, Lisbon
2024-06-06
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Almada, Lisbon, Porto
2024-06-06
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Lisbon, Matosinhos Municipality, Porto
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Coimbra, Lisbon
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Guimarães, Portimão, Leiria, Lisbon, Viana do Castelo, Viseu
2024-06-05
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Aveiro, Braga, Lisbon, Vila Nova de Gaia
2024-06-03
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan
Daiichi Sankyo
Phase 3
540
Coimbra, Guimarães, Lisbon, Porto
2024-05-21
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Braga, Lisbon
2024-05-21
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Lisbon, Porto
2024-05-19
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Lisbon
2024-05-15
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Santa Maria da Feira, Senhora da Hora, Braga, Lisbon
2024-05-13
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Lisbon, Porto
2024-05-08
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Braga, Coimbra, Lisbon, Matosinhos Municipality, Vila Nova de Gaia
2024-05-06
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
100
Coimbra, Lisbon, Porto
2024-04-30
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Braga, Canelas-V.N.Gaia, Carregado, Faro, Lisbon, Loures, Oeiras, Porto
2024-04-27
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Lisbon, Porto
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Braga, Coimbra, Lisbon, Matosinhos Municipality, Santa Maria da Feira
2024-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,200
Lisbon, Porto
2024-04-14
Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Observational
300
Lisbon
2024-04-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Lisbon, Porto
2024-04-10
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Lisbon, Ponte de Lima, Vila Nova de Gaia
2024-04-08
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Lisbon, Matosinhos Municipality, Coimbra, Porto
2024-04-03
Recruiting
Valvular Heart Disease in Women Registry
NCT07196930Valve Disease, Heart, Gender Bias, Guideline Adherence, Guideline Implementation
Valvular Heart Disease in Women Registry
Observational
800
Lisbon
2024-04-01
Recruiting
Gait Analysis and Degenerative Spine
NCT06335095Spinal Disease
Universidade Nova de Lisboa
Observational
200
Lisbon
2024-04-01
Active, closed
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207Heart Failure, Systemic Inflammation
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
673
Guilhufe - Penafiel, Lisbon, Setúbal
2024-04-01
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Coimbra, Faro, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2024-03-21
Recruiting
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
NCT06291896Women's Health: Neoplasm of Breast
Umbria Bioengineering Technologies
Not applicable
10,000
Lisbon
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Lisbon, Porto
2024-03-14
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
Braga, Lisbon, Porto
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Braga, Lisbon, Porto
2024-03-13
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Coimbra, Lisbon, Porto
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Amadora, Lisbon, Porto
2024-02-27
Active, closed
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757Coronary Artery Disease
Fundación EPIC
Observational
501
Carnaxide, Lisbon
2024-02-26
Recruiting
Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
NCT06307184Frozen Embryo Transfer
Instituto Valenciano de Infertilidade de Lisboa
Observational
530
Lisbon
2024-02-23
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
DrugDurvalumab
AstraZeneca
Phase 2
142
Lisbon
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Braga, Lisbon, Porto
2024-02-20
Active, closed
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096Delayed Graft Function
DrugEmpasiprubart
argenx
Phase 2
103
Carnaxide, Lisbon, Porto
2024-02-17
Recruiting
Effect of a Probiotic on the Female Genital Tract Microbiota of Participants With Fertility Disorders.
NCT06122207Fertility Disorders
ProbiSearch SL
Not applicable
120
Lisbon
2024-02-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Lisbon, Porto
2024-02-09
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide
Pfizer
Phase 3
492
Lisbon, Braga
2024-02-08
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
Lisbon, Vila Nova de Gaia, Porto
2024-02-05
Active, closed
Education and Literacy for an Active Life (Educação e Literacia Para Uma Vida Ativa)
NCT07100535Health Literacy, Physical Activity, Nutrition, Sedentary Behaviors
Lusofona University
Not applicable
128
Lisbon
2024-02-03
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Lisbon
2024-01-23
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
112
Lisbon, Porto
2024-01-19
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugsKerendia·Finerenone
Colorado Prevention Center
Phase 3
5,200
Covilha, Lisbon
2024-01-17
Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache
Hospital Universitari Vall d'Hebron Research Institute
Observational
700
Lisbon
2024-01-02
Recruiting
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
NCT06556446Ischemic Stroke
Insel Gruppe AG, University Hospital Bern
Observational
2,800
Lisbon
2024-01-01
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Braga, Lisbon, Porto
2023-12-31
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Braga, Lisbon, Porto
2023-12-30
Recruiting
Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
NCT06247085Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
70
Coimbra, Lisbon, Porto
2023-12-28
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Braga, Lisbon, Matosinhos Municipality
2023-12-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Coimbra, Lisbon, Porto
2023-12-21
Active, closed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475Cholangiocarcinoma
DrugTinengotinib
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Lisbon
2023-12-20
Recruiting
Improving CRT Outcome With Non-Invasive Cardiac Mapping
NCT05564793Heart Failure With Reduced Ejection Fraction
EP Solutions SA
Not applicable
330
Lisbon
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Vila Real, Faro, Lisbon
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Coimbra, Leiria, Lisbon, Porto
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga
Merck Sharp & Dohme LLC
Phase 3
1,314
Alcabideche, Vila Nova de Gaia, Braga, Lisbon, Porto
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Lisbon, Funchal, Vila Nova de Gaia
2023-12-15
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Lisbon, Vila Nova de Gaia
2023-12-15
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Lisbon, Porto
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Lisbon, Vila Nova de Gaia, Porto
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Braga, Coimbra, Guimarães, Lisbon, Matosinhos Municipality
2023-12-13
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2023-12-11
Recruiting
Validation of the C-mo System - Cough Monitoring
NCT05989698Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
Cough Monitoring Medical Solutions
Not applicable
300
Alfena, Amadora, Aveiro, Coimbra, Lisbon, Porto
2023-12-11
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Coimbra, Lisbon, Vila Nova de Gaia
2023-12-07
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Lisbon, Porto
2023-12-06
Recruiting
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
NCT06317805Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG
Phase 4
110
Lisbon
2023-12-06
Recruiting
Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)
NCT06741293Colorectal Cancer Screening, Colorectal Cancer (CRC), Microbiome
Gulbenkian Institute for Molecular Medicine
Observational
30,000
Lisbon
2023-11-28
Recruiting
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
NCT05809986Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Observational
174
Amadora, Guimarães, Leiria, Lisbon, Matosinhos Municipality, Ponte de Lima, Porto, Setúbal
2023-11-27
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Coimbra, Lisbon, Porto, Senhora da Hora
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Lisbon, Matosinhos Municipality, Porto
2023-11-16
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Almada, Lisbon, Porto
2023-11-14
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugsOpdivo·Nivolumab
Amgen
Phase 3
633
Setúbal, Lisbon, Porto
2023-11-02
Recruiting
Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
NCT05694572Cardiac Rhythm Disorder, Heart Failure, Sudden Cardiac Death
MicroPort CRM
Observational
2,500
Lisbon
2023-10-30
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Braga, Guarda, Lisbon
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Braga, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,109
Lisbon, Braga, Viana do Castelo, Viseu
2023-10-25
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Alcabideche, Lisboa, Amadora, Lisboa, Braga, Lisbon, Loures, Porto, Vila Real
2023-10-24
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Lisbon, Porto
2023-10-13
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Almada, Lisbon, Porto
2023-10-11
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real
2023-10-05
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
Carnaxide, Lisbon
2023-09-29
Active, closed
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Urothelial Carcinoma
DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Braga, Lisbon
2023-09-22
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
DrugsLurbinectedin·Doxorubicin
PharmaMar
Phase 3
469
Lisbon, Coimbra, Porto
2023-09-21
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Faro, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-09-14
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941Sjögren's Syndrome
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
774
Lisbon
2023-09-11
Active, closed
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 2
268
Lisbon
2023-09-08
Recruiting
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT06006117Marginal Zone Lymphoma
DrugsMosunetuzumab·Bendamustine·Lenalidomide·Rituximab
The Lymphoma Academic Research Organisation
Phase 3
260
Lisbon
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Carnaxide, Lisbon
2023-09-01
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Creixomil, Aveiro, Lisbon
2023-08-31
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Lisbon, Porto
2023-08-21
Active, closed
Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.
NCT05196269Breast Cancer
Fundacao Champalimaud
Not applicable
1,030
Lisbon
2023-08-08
Recruiting
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
NCT05287945Carcinoma, Renal Cell
Oncorena AB
Phase 1/2
75
Lisbon
2023-08-04
Active, closed
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740Multiple Sclerosis
DrugsMavenclad·Cladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Observational
366
Coimbra, Lisbon, Porto
2023-08-03
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Almada, Coimbra, Lisbon
2023-08-01
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Lisbon, Porto
2023-07-19
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Guimarães, Lisbon, Torres Vedras, Matosinhos Municipality
2023-07-11
Active, closed
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
210
Lisbon, Porto
2023-07-07
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Lisbon
2023-07-05
Recruiting
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
NCT04861805Symptomatic Aortic Stenosis
P+F Products + Features GmbH
Not applicable
267
Lisbon, Carnaxide, Vila Nova de Gaia, Evora
2023-07-03
Recruiting
Global Research Initiative for Patients Screening on MASH
NCT05651724MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
Julius Clinical
Observational
10,000
Lisbon
2023-06-30
Recruiting
International Cardiac Amyloidosis Registry
NCT06894290Cardiac Amyloidosis
Leiden University Medical Center
Observational
300
Lisbon
2023-06-30
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
451
Amadora, Faro, Guarda, Guimarães, Lisbon, Vila Nova de Gaia
2023-06-26
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Lisbon, Porto
2023-06-22
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Lisbon, Porto
2023-06-21
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320Episodic Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
315
Braga, Coimbra, Lisbon, Porto
2023-06-08
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Lisbon, Porto
2023-06-07
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
Lisbon, Porto
2023-05-31
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Lisbon, Matosinhos Municipality, Porto
2023-05-31
Recruiting
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466Asthma
DrugBudesonide
Novartis Pharmaceuticals
Phase 3
200
Lisbon, Porto
2023-05-11
Recruiting
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100Focal Onset Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
360
Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Vila Real
2023-05-09
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol
Gilead Sciences
Phase 3
654
Braga, Guimarães, Lisbon, Matosinhos Municipality
2023-05-08
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira
2023-04-25
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Coimbra, Lisbon, Porto
2023-04-17
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Coimbra, Covilha, Figueira da Foz Municipality, Lisbon, Santa Maria da Feira, Torres Novas, Vila Nova de Gaia, Vila Real
2023-04-11
Active, closed
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05704049Relapsed/Refractory Multiple Myeloma
DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab
Sanofi
Phase 2
118
Braga, Lisbon
2023-04-05
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
DrugDarolutamide
Bayer
Phase 3
985
Coimbra, Lisbon
2023-04-03
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Almada, Braga, Lisbon, Porto, Vila Nova de Gaia
2023-03-29
Recruiting
Radiographic Head and Neck Positional Changes in Response to Usage of Low-powered Prismatic Lenses
NCT07532642Postural Neck Pain, Postural Imbalance, Postural Disorders
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Not applicable
20
Lisbon
2023-03-27
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Coimbra, Lisbon, Vila Nova de Gaia
2023-03-23
Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Lisbon
2023-03-21
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Almada, Carnaxide, Coimbra, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira, Setúbal
2023-03-09
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Braga, Lisbon, Vila Nova de Gaia
2023-03-02
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Braga, Coimbra, Covilha, Guimarães, Lisbon, Porto, Pragal, Santa Maria da Feira
2023-02-15
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
160
Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Coimbra, Lisbon, Porto
2023-02-13
Active, closed
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899High-risk Large B-cell Lymphoma (LBCL)
DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin
Kite, A Gilead Company
Phase 3
300
Lisbon, Porto
2023-02-10
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Braga, Lisbon, Porto
2023-02-08
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Lisbon, Torres Vedras
2023-02-03
Recruiting
Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD
NCT04433052Coronary Heart Disease
Tampere University
Not applicable
12,000
Carnaxide, Lisbon
2023-02-01
Recruiting
Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
NCT06778343Ankylosing Spondylitis, Rheumatic Arthritis, Systemic Lupus Erythematosus
Universidade Nova de Lisboa
Observational
134
Lisbon
2023-01-31
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Braga, Guimarães, Lisbon, Viana do Castelo
2023-01-16
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
Lisbon, Vila Nova de Gaia
2023-01-12
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Lisbon, Porto
2023-01-11
Recruiting
The Triad of Nutrition, Intestinal Microbiota and Rheumatoid Arthritis (TASTY)
NCT06758817Diet Interventions
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Not applicable
100
Lisbon
2023-01-02
Active, closed
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 2
68
Guimarães, Lisbon
2022-12-29
Recruiting
European Myeloma Network (EMN) Sample Project
NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
European Myeloma Network B.V.
Observational
6,000
Coimbra, Lisbon, Porto
2022-12-21
Recruiting
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
NCT05633810Diabete Type 2, Cardiovascular Diseases
DrugsColchicine·Aspirin
Montreal Heart Institute
Phase 3
10,000
Amadora, Lisbon
2022-12-21
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Greenwich LifeSciences, Inc.
Phase 3
2,250
Lisbon
2022-12-16
Recruiting
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
DrugBlinatumomab
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Lisbon
2022-12-15
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
885
Aveiro, Lisbon, Porto, Santa Maria da Feira
2022-12-13
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Guimarães, Lisbon, Porto
2022-11-30
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Lisbon
2022-11-23
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Lisbon, Porto
2022-11-08
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Lisbon, Porto, Sacavém
2022-11-04
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Braga, Lisbon, Porto
2022-10-25
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
DrugsTucatinib·Erbitux·Herceptin·Avastin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Almada, Guarda, Lisbon, Porto
2022-10-24
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Loures, Braga, Coimbra, Lisbon, Porto
2022-10-14
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Gaia, Guimarães, Lisbon, Porto
2022-10-14
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Amadora, Lisbon, Senhora da Hora
2022-10-12
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Almada, Lisbon, Vila Nova de Gaia
2022-10-04
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Loures, Lisbon, Porto, Porto Covo
2022-10-04
Recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Cytarabine·Azacitidine·Fludarabine
PedAL BCU, LLC
Phase 3
130
Lisbon
2022-10-01
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Braga, Lisbon, Porto
2022-09-27
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
Braga, Lisbon, Porto
2022-09-20
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
Lisbon, Loures, Portimão, Santa Maria da Feira, Vila Nova de Gaia
2022-09-19
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 2/3
450
Coimbra, Lisbon, Porto, Viana do Castelo
2022-09-13
Recruiting
Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis
NCT04098146Mandibular Reconstruction, Segmental Mandibular Defects
AO Innovation Translation Center
Observational
300
Lisbon
2022-09-12
Recruiting
EPOS Discoid Meniscus (DiMe) Project
NCT05580315Discoid Meniscus of Knee
University of Milano Bicocca
Observational
500
Coimbra, Lisbon
2022-09-08
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Braga, Lisbon, Porto, Vila Real
2022-09-08
Active, closed
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940Colorectal Cancer
DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab
Exelixis
Phase 3
901
Almada, Coimbra, Guimarães, Lisbon
2022-09-07
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Lisbon, Porto
2022-08-30
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Lisbon, Porto
2022-08-22
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Funchal, Almada, Faro, Lisbon, Loures, Porto, Viseu
2022-08-15
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Carnaxide, Coimbra, Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Braga, Lisbon, Senhora da Hora
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Lisbon, Portimão, Porto, Santa Maria da Feira
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Lisbon, Braga, Porto
2022-07-21
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab
Hoffmann-La Roche
Phase 3
922
Coimbra, Lisbon, Loures, Porto
2022-07-18
By invitation
LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)
NCT04762992Fetal Growth Retardation, Prematurity, Pre-Eclampsia
DrugEnoxaparin
Centro Hospitalar de Lisboa Central
Phase 3
12
Lisbon
2022-07-18
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
DrugsDepemokimab·Mepolizumab
GlaxoSmithKline
Phase 3
163
Lisbon, Porto
2022-07-14
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Lisbon, Porto
2022-07-08
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib
Novartis Pharmaceuticals
Phase 4
134
Lisbon, Loures, Porto
2022-07-07
Recruiting
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05203172Solid Tumors
Pfizer
Phase 4
210
Lisbon, Porto
2022-07-05
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
DrugNexium
AstraZeneca
Phase 3
53
Coimbra, Lisbon, Porto, Viana do Castelo
2022-07-01
Recruiting
Post COVID-19 Condition
NCT05531773COVID-19
Euresist Network GEIE
Observational
2,300
Lisbon
2022-07-01
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Coimbra, Lisbon, Porto
2022-06-23
Recruiting
CytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
CytoSorbents, Inc
Observational
3,000
Coimbra, Lisbon
2022-06-22
Active, closed
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
NCT05115110Spinal Muscular Atrophy (SMA)
DrugsRO7204239·Risdiplam
Hoffmann-La Roche
Phase 2/3
97
Lisbon
2022-06-02
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia
2022-05-30
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Lisbon, Porto
2022-05-23
Active, closed
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703Relapsing-remitting Multiple Sclerosis
DrugsFingolimod·Ocrelizumab
Hoffmann-La Roche
Phase 3
188
Braga, Coimbra, Lisbon
2022-05-19
Active, closed
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
NCT05296746Breast Cancer Stage II
DrugRibociclib
SOLTI Breast Cancer Research Group
Phase 2
1,100
Lisbon, Porto
2022-05-03
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Braga, Coimbra, Lisbon, Pragal
2022-05-03
Active, closed
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
NCT05270044Melanoma
Pierre Fabre Medicament
Phase 3
815
Lisbon, Porto
2022-05-02
Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617Seizures, Lennox Gastaut Syndrome
SK Life Science, Inc.
Phase 3
252
Lisbon, Porto, Almada
2022-04-28
Recruiting
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616Hodgkin Lymphoma
DrugsVinblastine·Filgrastim·Pegfilgrastim·Bleomycin
University College, London
Phase 3
1,042
Lisbon
2022-04-14
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550Non-small Cell Lung Cancer
DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab
AstraZeneca
Phase 2
630
Lisbon, Porto
2022-04-14
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
DrugRusfertide
Protagonist Therapeutics, Inc.
Phase 3
293
Almada, Braga, Lisbon, Porto
2022-04-01
Active, closed
Interference of Endurance Training on Strength Development and Neuromuscular Adaptations
NCT06378762Exercise
University of Lisbon
Not applicable
30
Lisbon
2022-04-01
Recruiting
Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)
NCT05534009COVID-19
Euresist Network GEIE
Observational
1,800
Lisbon
2022-04-01
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Amadora, Lisbon, Loures
2022-03-30
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Lisbon, Vila Real
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Lisbon, Porto
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide
Merck Sharp & Dohme LLC
Phase 3
460
Lisbon, Porto
2022-03-24
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
DrugApremilast
Amgen
Phase 3
60
Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2022-03-17
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Braga, Carnaxide, Lisbon, Porto
2022-03-15
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Lisbon, Porto
2022-03-08
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Braga, Lisbon, Coimbra
2022-03-07
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
DrugsDato-DXd·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
740
Lisbon, Porto
2022-03-04
Recruiting
Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project
NCT05463380COVID-19
Euresist Network GEIE
Observational
22,000
Lisbon
2022-02-23
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Lisbon, Porto
2022-02-21
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Lisbon, Loures, Porto
2022-02-07
Active, closed
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287Autosomal Dominant Hypocalcemia
Calcilytix Therapeutics, Inc., a BridgeBio company
Observational
95
Lisbon
2022-01-20
Recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Not applicable
608
Lisbon
2022-01-18
Active, closed
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
151
Lisbon, Porto
2022-01-04
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Coimbra, Lisbon, Porto
2021-12-17
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Braga, Coimbra, Leiria, Lisbon, Matosinhos Municipality, Santa Maria da Feira
2021-12-13
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Erbitux·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-12-10
Active, closed
EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke
NCT05029414Acute Ischemic Stroke
University Hospital, Basel, Switzerland
Not applicable
543
Lisbon
2021-12-09
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil
Jazz Pharmaceuticals
Phase 3
920
Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto
2021-12-02
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Lisbon, Porto
2021-12-01
Recruiting
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3
534
Lisbon, Porto
2021-11-30
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Alcabideche, Almada, Carnaxide, Coimbra, Guimarães, Leiria, Lisbon, Matosinhos Municipality
2021-11-23
Active, closed
Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction
NCT03849586Erectile Dysfunction
European Association of Urology Research Foundation
Observational
1,076
Lisbon
2021-11-19
Active, closed
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
NCT05130450Familial Chylomicronemia Syndrome
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
60
Creixomil, Lisbon
2021-11-18
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Coimbra, Lisbon, Matosinhos Municipality, Porto
2021-11-17
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
DrugEfgartigimod PH20
argenx
Phase 3
173
Lisbon, Porto, Vila Nova de Gaia
2021-11-17
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Lisbon, Loures, Porto
2021-11-17
Active, closed
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
DrugBlinatumomab
Amgen
Phase 3
303
Coimbra, Lisbon, Porto
2021-11-02
Active, closed
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
389
Lisbon
2021-10-27
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Lisbon, Porto
2021-10-25
Recruiting
Biomarkers for Ventilator-associated Pneumonia
NCT05117125Pneumonia, Ventilator-Associated
Region Skane
Observational
1,000
Lisbon
2021-10-15
Active, closed
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818Multiple Sclerosis (MS)
DrugsSiponimod·Fingolimod·Ofatumumab
Novartis Pharmaceuticals
Phase 3
129
Coimbra, Lisbon
2021-10-05
Active, closed
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
NCT04884815Wilson Disease
Ultragenyx Pharmaceutical Inc
Phase 1/2
82
Lisbon, Porto
2021-09-27
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
282
Braga, Lisbon, Porto
2021-09-23
Active, closed
A Non-interventional Cohort Safety Study of Patients With hATTR-PN
NCT04850105Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics
Observational
202
Lisbon
2021-09-21
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Braga, Guarda, Lisbon, Ponte de Lima, Porto
2021-08-30
Rows per page Showing 1–500 of 683
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/lisbon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 683 of those studies with a site in Lisbon.

How many clinical trials are recruiting in Lisbon?

331 of the 683 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 29 have not yet opened recruitment, 303 are active but closed to new participants, and 20 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lisbon), 683 studies
PhaseStudiesRecruitingShare
Phase 336914454%
Observational1167617%
Not applicable784211.4%
Phase 264329.4%
Phase 2/319112.8%
Phase 1/216132.3%
Phase 41381.9%
Phase 1851.2%

Most active sponsors

Lead sponsors with the most studies (Lisbon)
Lead sponsorStudiesRecruiting
AstraZeneca3312
Janssen Research & Development, LLC3211
Merck Sharp & Dohme LLC2815
Hoffmann-La Roche275
Novartis Pharmaceuticals2714
AbbVie238
Amgen198
Boehringer Ingelheim1711
Bristol-Myers Squibb157
Sanofi153
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.